A Prospective Study to Observe Clinical Outcomes in Patients Receiving Antiplatelet or Anticoagulant Therapy for Cancer-Associated Acute Ischemic Stroke

Condition(s) studied

Study summary

The goal of this observational study is to learn about the effectiveness and safety of antiplatelet and anticoagulant treatments in people with a history of cancer who have acute ischemic stroke. The main questions it aims to answer are:

* Are there differences in the risk of another stroke between people receiving antiplatelet treatment and those receiving anticoagulant treatment?
* Are there differences in the risk of bleeding between the treatment groups?
* Which clinical characteristics, imaging findings, cancer-related factors, and blood test results are associated with treatment outcomes?

Participants will:

* Receive antiplatelet treatment, anticoagulant treatment, or a combination of both, as selected by their treating physicians during routine clinical care.
* Provide clinical information and blood samples for the study.
* Complete follow-up assessments approximately 30, 90, 180, and 360 days after the stroke.

Researchers will compare recurrent stroke, bleeding, other blood clot-related events, functional recovery, and survival among participants receiving different antithrombotic treatments. The study will not assign or change participants' treatments.

Eligibility

Primary outcome measure(s)

• Number of Participants With Recurrent Stroke — 30 days, 90 days, 180 days, and 360 days after enrollment
  Recurrent stroke is defined as a new acute neurological deficit consistent with ischemic or hemorrhagic stroke occurring after enrollment and confirmed by clinical evaluation and brain imaging. Events will be assessed during follow-up visits at 30, 90, 180, and 360 days.
• Number of Participants With Symptomatic Intracranial Hemorrhage — 30 days, 90 days, 180 days, and 360 days after enrollment
  Symptomatic intracranial hemorrhage is defined as a newly detected intracranial hemorrhage on brain imaging that is associated with neurological deterioration or other clinically relevant symptoms. Events will be assessed during follow-up visits at 30, 90, 180, and 360 days.
• Number of Participants With Major Extracranial Bleeding — 30 days, 90 days, 180 days, and 360 days after enrollment
  Major extracranial bleeding includes clinically significant bleeding outside the cranial cavity that results in death, occurs in a critical organ or site, requires blood transfusion, or causes a clinically significant decrease in hemoglobin. Events will be assessed during follow-up visits at 30, 90, 180, and 360 days.

Trial sites (1)

More Xuanwu Hospital, Beijing trials in China

Other trials for the same condition